A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
OBJECTIVE
Type 2A von Willebrand's disease (VWD) refers to disease variants with decreased platelet-dependent function of von Willebrand factor (VWF) associated with the absence of high molecular weight (HMW) multimers. The candidate G1629R mutation, identified in an Italian patient with type 2A VWD, was expressed to confirm the relationship between phenotype and genotype.


METHODS
Plasma samples from the patient were studied after DDAVP or FVIII/VWF concentrate injections. Furthermore, an expression vector carrying the G1629R mutation was constructed by site-directed mutagenesis and transiently expressed in Cos-7 cells. The characteristics of the corresponding recombinant protein were analyzed.


RESULTS
After 1-deamino-8-D-argine vasopressin (DDAVP) infusion, factor VIII and VWF activities increased and HMW VWF multimers were transiently observed in the patient's plasma. VWF activity increased only after administration of a dual FVIII/VWF concentrate. ADAMTS-13 activity did not change significantly before or after the therapies. Secretion, in culture medium, of the corresponding mutated protein (R1629-rVWF) was slightly decreased and this rVWF contained intermediate and HMW multimers. Furthermore, binding of R1629-rVWF to platelet GPIb was moderately reduced compared to that of the wild-type rVWF.


CONCLUSIONS
Based on the DDAVP and in vitro expression results, we classified the G1629R mutation in group 2 type 2A mutations. Our findings could explain why DDAVP may only be partially effective and suggest that FVIII/VWF concentrates should be used in cases of prolonged mucosal bleeding and major surgery when functional VWF is required.
Hilbert
Lysiane
L
Preclinical Department, LFB, Lille, France. hilbert@lfb.fr <hilbert@lfb.fr>
Federici
Augusto B
AB
Baronciani
Luciano
L
Dallagiovanna
Serena
S
Mazurier
Claudine
C
D051722:ADAM Proteins / Q000097:blood; D000071120:ADAMTS13 Protein; D019943:Amino Acid Substitution; D000818:Animals; D001704:Biopolymers; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000378:metabolism; D019556:COS Cells; D002522:Chlorocebus aethiops; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004338:Drug Combinations; D004351:Drug Resistance; D005169:Factor VIII / Q000627:therapeutic use; D005838:Genotype; D005884:Gingival Hemorrhage / Q000209:etiology; D006801:Humans; D008970:Molecular Weight; D020125:Mutation, Missense; D010641:Phenotype; D017354:Point Mutation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D014081:Tooth Extraction / Q000009:adverse effects; D014842:von Willebrand Diseases / Q000145:classification / Q000188:drug therapy / Q000235:genetics*; D014841:von Willebrand Factor / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use
D001704:Biopolymers; D004338:Drug Combinations; D011993:Recombinant Fusion Proteins; C509423:factor VIII, von Willebrand factor drug combination; D014841:von Willebrand Factor; D005169:Factor VIII; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human; D003894:Deamino Arginine Vasopressin